![nopic_lg](https://wallstreet.no/wp-content/uploads/2023/07/nopic_lg.gif)
This biotechnology company has seen 2 positive estimate revisions in the last 30 days. The Zacks Consensus Estimate has also moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s rally can turn into more strength down the road.
Athersys currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Investors interested in the bio-med/gene industry may also consider Affymetrix Inc. (AFFX) which sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment